Kronos Bio, Inc. (NASDAQ:KRON - Get Free Report) saw a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 611,600 shares, a drop of 18.2% from the March 15th total of 748,000 shares. Currently, 1.6% of the shares of the company are short sold. Based on an average daily volume of 188,000 shares, the days-to-cover ratio is presently 3.3 days.
Kronos Bio Stock Performance
Shares of KRON traded down $0.01 during mid-day trading on Friday, reaching $0.85. 104,041 shares of the company's stock traded hands, compared to its average volume of 244,698. Kronos Bio has a 12 month low of $0.69 and a 12 month high of $1.60. The stock has a market capitalization of $51.88 million, a P/E ratio of -0.60 and a beta of 1.78. The business's 50-day moving average price is $0.89 and its 200-day moving average price is $0.94.
Kronos Bio (NASDAQ:KRON - Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.13). Kronos Bio had a negative net margin of 867.66% and a negative return on equity of 64.55%. The business had revenue of $2.27 million for the quarter, compared to the consensus estimate of $1.00 million. Equities research analysts anticipate that Kronos Bio will post -1.36 EPS for the current year.
Hedge Funds Weigh In On Kronos Bio
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Velan Capital Investment Management LP acquired a new stake in shares of Kronos Bio in the 4th quarter worth approximately $33,000. GTS Securities LLC acquired a new stake in Kronos Bio in the fourth quarter worth approximately $48,000. Squarepoint Ops LLC acquired a new stake in Kronos Bio in the fourth quarter worth approximately $93,000. Kennedy Capital Management LLC boosted its stake in Kronos Bio by 8.7% during the 4th quarter. Kennedy Capital Management LLC now owns 149,251 shares of the company's stock valued at $142,000 after purchasing an additional 12,007 shares in the last quarter. Finally, Gilead Sciences Inc. acquired a new position in shares of Kronos Bio during the 4th quarter valued at $179,000. Institutional investors own 64.09% of the company's stock.
About Kronos Bio
(
Get Free Report)
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
See Also
Before you consider Kronos Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kronos Bio wasn't on the list.
While Kronos Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
